Certara (NASDAQ:CERT) Updates FY 2024 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 0.410-0.440 for the period, compared to the consensus EPS estimate of 0.410. The company issued revenue guidance of $380.0 million-$385.0 million, compared to the consensus revenue estimate of $386.2 million. Certara also updated its FY24 guidance to $0.41-0.44 EPS.

Analyst Ratings Changes

CERT has been the topic of several research reports. Robert W. Baird dropped their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, September 27th. Finally, Barclays decreased their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Certara currently has a consensus rating of “Hold” and a consensus target price of $15.92.

Certara Trading Up 0.4 %

Shares of NASDAQ:CERT traded up $0.04 during trading on Friday, reaching $11.03. 1,081,810 shares of the company traded hands, compared to its average volume of 1,148,975. Certara has a 1-year low of $9.99 and a 1-year high of $19.87. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The firm has a fifty day simple moving average of $11.02 and a 200 day simple moving average of $13.70.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter in the previous year, the business posted $0.06 EPS. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. Analysts predict that Certara will post 0.27 EPS for the current fiscal year.

Insider Activity

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.